Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514256000 1,3-diazines (e.g., pyrimidines, etc.) 2366
514252100 1,4 diazines 1888
514248000 Polycyclo ring system having a 1,2- or 1,4-diazine as one of the cyclos 969
514252010 1,2 diazine attached directly or indirectly to an additional hetero ring by nonionic bonding 312
Entries
DocumentTitleDate
20100113457NOVEL PYRIDAZINE DERIVATIVES - The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R05-06-2010
20100075972AGENT FOR TREATMENT OF MULTIPLE SCLEROSIS - To provide a preventive and/or therapeutic drug for multiple sclerosis, which has high efficacy against multiple sclerosis, which exhibits excellent safety, and which can be orally administered.03-25-2010
20100041661CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD - The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.02-18-2010
20090270399NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1):10-29-2009
20090270398Compounds, Compositions and Methods Comprising Pyridazine Derivatives - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formula I) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.10-29-2009
20090233934Pyrazinecarboxamide Derivatives and Plant Disease Controlling Agents Containing the Same - The present invention provides the compounds represented by the general formula (I):09-17-2009
20090042888Prostaglandin endoperoxide H synthase biosynthesis inhibitors - The present invention describes pyridazinone compounds of formula I02-12-2009
20110281876THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula:11-17-2011
20110301166METHOD FOR THE PREVENTION OF THROMBOEMBOLIC DISORDERS - A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.12-08-2011
20100016324PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE - There are disclosed pharmaceutical compositions for topical administration or for use in mesotherapy, containing a PDE3 inhibitor as active ingredient, and their use in the treatment of cellulite.01-21-2010
20090181973Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas - The present invention relates to a medicinal composition for preventing or treating pancreatic cancer, comprising 3-alkoxy-6-allylthiopyridazine or a pharmaceutically acceptable salt thereof as an effective ingredient. An MTT assay, to assess the viability of cells, and flow cytometric analysis, to measure apoptotic cell death, were performed, and the results, which revealed that the compound and pharmaceutically acceptable salts thereof have preventive and therapeutic activity against pancreatic cancer, are presented herein.07-16-2009
20100286150LEVOSIMENDAN FOR USE IN TREATING CHRONIC VALVULAR DISEASE - A method for the treatment of chronic valvular disease (CVD) in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of levosimendan or a pharmaceutically acceptable salt thereof. Levosimendan was shown to significantly reduce mortality and to significantly improve quality of life in dogs suffering from chronic valvular disease.11-11-2010
20090281106PROPHYLACTIC AND/OR THERAPEUTIC METHOD FOR RHEUMATOID ARTHRITIS - The present invention provides a prophylactic and/or therapeutic agent for rheumatoid arthritis comprising 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and leflunomide in combination.11-12-2009
20080275050Pyridazine Compound and Use Thereof - A pyridazine compound represented by the formula (1):11-06-2008
20090298835NOVEL SCAFFOLDS FOR ALPHA-HELIX MIMICRY - Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins.12-03-2009
20090005384Method for Producing Adsorptive Porous Body - The present invention relates to a method for producing a 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one adsorptive porous material characterized by treating a porous material with a halogen-containing organic solvent in which 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one is dissolved. The production method of the present invention is simple and easy, and the obtained adsorptive porous material is excellent in dissolution properties of 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one.01-01-2009
20080318959Compounds that Inhibit Hiv Particle Formation - The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV.12-25-2008
20090203701PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - A medicament having excellent therapeutic and prophylactic effects on rheumatoid arthritis is provided.08-13-2009
20090209542HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are compounds of the Formula I08-20-2009
20090318455COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS - Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.12-24-2009
20090069332NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS - This invention relates to pyridazine derivatives represented by the formula (1):03-12-2009
20090221588FUNGICIDAL COMPOSITIONS - A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of Formula (I) or a compound of Formula (II) wherein R09-03-2009
20100063053HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF - Disclosed are compounds of the Formulas I and V03-11-2010
20100009991POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS - The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.01-14-2010
20100004247COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 - The present invention relates to a therapeutic combination comprising a MEK inhibitor and an Aurora kinase inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a therapeutic combination comprising a MEK inhibitor and an Aurora kinase inhibitor; a combination product comprising a MEK inhibitor and an Aurora kinase inhibitor, a kit of parts comprising a MEK inhibitor and an Aurora kinase inhibitor; use of a therapeutic combination, combination product or kit of parts in the treatment of cancer; a method of treating cancer comprising administering the therapeutic combination, combination product or kit of parts to a patient. The therapeutic combination and methods of the invention are also useful in the treatment of conditions in which the inhibition of MEK and/or Aurora kinase is beneficial.01-07-2010
20120010207Chemical Compounds - The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.01-12-2012
20110065710Insecticidal N-(Heteroarylalkyl)Alkanediamine Derivatives - Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, R03-17-2011
20120135995FUNGICIDAL DIPHENYL-SUBSTITUTED PYRIDAZINES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,05-31-2012
20090131443METHOD FOR PREVENTION AND/OR TREATMENT OF RHEUMATOID ARTHRITIS - The invention provides a method for the prevention and/or treatment of rheumatoid arthritis, characterized in that the method comprises administering an IL-1β inhibitor and a calcineurin inhibitor, and a preventive and/or therapeutic medicine for rheumatoid arthritis including an IL-1β inhibitor and a calcineurin inhibitor in combination.05-21-2009
20090306081Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds - The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. The invention also provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound or a pharmaceutically acceptable salt thereof and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation.12-10-2009
20110237595DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS - The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ischaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula (I):09-29-2011
20080214549N-Substituted Glycine Derivatives: Hydroxylase Inhibitors - The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I)09-04-2008
20080221109PESTICIDAL SUBSTITUTED THIOETHERS - The invention relates to the use of thioether derivatives of formula (I) wherein: R09-11-2008
20130137691DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS - The invention relates to compounds of formula (I):05-30-2013
20130137692PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition containing a pyridazine compound represented by formula (I):05-30-2013
20130131067PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition, containing a carboxamide compound represented by formula (I):05-23-2013
20120071483THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELL STRESS RESPONSE - The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate cell stress response for treating said disease.03-22-2012

Patent applications in class Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)

Patent applications in all subclasses Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.)